Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X; Hellenic Cooperative Group. Tsimberidou AM, et al. Among authors: sakellari i. Cancer. 2003 Apr 1;97(7):1721-31. doi: 10.1002/cncr.11240. Cancer. 2003. PMID: 12655529 Free article. Clinical Trial.
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
Asteris PG, Gandomi AH, Armaghani DJ, Tsoukalas MZ, Gavriilaki E, Gerber G, Konstantakatos G, Skentou AD, Triantafyllidis L, Kotsiou N, Braunstein E, Chen H, Brodsky R, Touloumenidou T, Sakellari I, Alkayem NF, Bardhan A, Cao M, Cavaleri L, Formisano A, Guney D, Hasanipanah M, Khandelwal M, Mohammed AS, Samui P, Zhou J, Terpos E, Dimopoulos MA. Asteris PG, et al. Among authors: sakellari i. J Cell Mol Med. 2024 Feb;28(4):e18105. doi: 10.1111/jcmm.18105. J Cell Mol Med. 2024. PMID: 38339761 Free PMC article.
Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP, Tsirigotis P, Stavroyianni N, Argyropoulos KV, Girkas K, Pappa V, Chondropoulos S, Papadavid E, Sakellari I, Anagnostopoulos A, Antoniou C, Dervenoulas J. Siakantaris MP, et al. Among authors: sakellari i. Transfus Apher Sci. 2012 Apr;46(2):189-93. doi: 10.1016/j.transci.2011.10.029. Epub 2011 Dec 16. Transfus Apher Sci. 2012. PMID: 22178592
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A. Pavlů J, et al. Among authors: sakellari i. Cancer. 2017 Jun 1;123(11):1965-1970. doi: 10.1002/cncr.30604. Epub 2017 Feb 17. Cancer. 2017. PMID: 28211939 Free article.
The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I, Batsis I, Bousiou Z, Mallouri D, Constantinou V, Gavriilaki E, Smias C, Yannaki E, Kaloyannidis P, Papaioannou G, Stavroyianni N, Syrigou A, Sotiropoulos D, Fylaktou A, Tsompanakou A, Saloum R, Anagnostopoulos A. Sakellari I, et al. Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):658-666. doi: 10.1016/j.clml.2017.06.008. Epub 2017 Jun 29. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28716402
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
Sakellari I, Gavriilaki E, Iskas M, Bousiou Z, Chatziioannidis A, Batsis I, Mallouri D, Constantinous V, Stavroyianni N, Syrigou A, Marvaki A, Pilavaki M, Papaemmanouel S, Anagnostopoulos A. Sakellari I, et al. Hematol Oncol. 2019 Oct;37(4):490-492. doi: 10.1002/hon.2645. Epub 2019 Jul 24. Hematol Oncol. 2019. PMID: 31339579 Clinical Trial. No abstract available.
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, Douka V, Marvaki A, Karypidis K, Iskas M, Baliakas P, Kaloyannidis P, Yannaki E, Sotiropoulos D, Kouvatseas G, Smias C, Anagnostopoulos A. Sakellari I, et al. Leuk Lymphoma. 2015;56(11):3071-81. doi: 10.3109/10428194.2015.1028054. Epub 2015 Apr 7. Leuk Lymphoma. 2015. PMID: 25760637
Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I, Mallouri D, Gavriilaki E, Batsis I, Kaliou M, Constantinou V, Papalexandri A, Lalayanni C, Vadikolia C, Athanasiadou A, Yannaki E, Sotiropoulos D, Smias C, Anagnostopoulos A. Sakellari I, et al. Biol Blood Marrow Transplant. 2017 Mar;23(3):445-451. doi: 10.1016/j.bbmt.2016.11.023. Epub 2016 Nov 30. Biol Blood Marrow Transplant. 2017. PMID: 27914967 Free article.
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Tsirigotis P, et al. Among authors: sakellari i. Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882363
132 results